Translational Pathway Program


The ISCT 2024 Vancouver Translational Pathway Program will feature an extraordinary lineup of five plenaries and 20 concurrent sessions bringing together leading global experts to present preclinical research with high-impact potential, and promising results across phases of clinical trials.

Join us in Vancouver to dive deep into cutting-edge data, uncover groundbreaking innovations and hear from experts on the status of the field and their predictions on its future direction.

La présidentielle showcases the focus and vision of leaders from sister scholarly societies with a focused interest in discovery, development and clinical deployment of Cell & Gene Therapy cures.

Anna Sureda, MD, PhD – President of EBMT – will speak to the unique opportunities and challenges of CGT deployment in the European context. A mirrored American perspective will be provided by Corey Cutler, MD, MPH – President of ASTCT. Amander Clark, PhD – President of ISSCR – will speak to the emerging use of iPSCs as tools and therapies. All will also provide these views in the context of their own research programs.


Addresses scientific advances, emerging cell and cell-based therapeutic platforms, as well as technological developments in pre-clinical CGT research with clinical implications.


The basic and translational science underlying cell and gene therapies continues to evolve at a breathtaking pace.  Traditional avenues of investigation are rapidly expanding to encompass cutting edge areas including tissue engineering, artificial intelligence and machine-based learning, and advances in imaging and tracking technologies.

Join us as we explore these and other novel technologies and see how these will lead to both better mechanistic knowledge and to future clinical successes.


Extracellular Vesicles: Potential Tools for Targeted Gene Editing In Vivo

CHAIR: Bernd Giebel, PhD, University of Duisburg-Essen, Germany


  • Samir El-Andaloussi, PhD, Karolinska Institutet, Sweden
  • Olivier G. de Jong, PhD, Utrecht University, Netherlands
  • Houjian Cai, PhD, University of Georgia, United States

Beyond the Dead (MSCs)

CHAIR: Daniel J. Weiss, MD, PhD, University of Vermont, United States


  • James Ankrum, PhD, University of Iowa, United States
  • Tracy Heng, PhD, Monash University, Australia
  • Francesco Dazzi, MD, PhD, AstraZeneca, United Kingdom

MSC Route of Delivery

CHAIR: Manoj Lalu, MD, PhD, FRCPC, The Ottawa Hospital Research Institute, Canada


  • Mark Lowdell, PhD, FRCPath, FRSB, University College London, United Kingdom
  • Sara McCoy, MD, PhD, University of Wisconsin, United States
  • Sowmya Viswanathan, PhD, University Health Network, Canada

Emerging Technologies in Cell Therapy

CHAIR: Alice Bertaina, MD, PhD, Stanford Medicine, United States


  • R. Chase Cockrell, PhD, University of Vermont, United States
  • Will Johnson, PhD, Asimov Inc., United States
  • Andras Nagy, PhD, Lunenfeld-Tanenbaum Research Institute, Canada

Advanced Techniques for Regenerative Medicine

CHAIR: Rachel Burga, PhD, Obsidian Therapeutics, United States


  • Finn Hawkins, M.B. B.Ch., Boston University, United States
  • Nika Shakiba, PhD, University of British Columbia, Canada
  • Katja Gabriele Weinacht, MD, PhD, Stanford Medicine, United States


This segment addresses topics arising in moving from pre-clinical research to First in Human studies, including results from promising Phase I clinical trials, process development, clinical trial development with an eye to eventual market-authorization and product launch, early-stage CMC, regulatory requirements, and sustainable business models.


Cell and gene therapies have evolved from an academic concept to a full-fledged reality, reshaping the landscape of intractable disease treatment. This plenary will delve into the transformative potential of these revolutionary treatments for diseases such as Parkison's, blood cancers, and autoimmune diseases. 

Explore current manufacturing and regulatory challenges and how they are being tackled. Keep up with recent advances and challenges in the development of cellular nanoparticles for therapeutic applications. Join us in unravelling the potential and complexities of these groundbreaking treatments that are at the forefront of medical innovation.


The State of iPSC-Derived Cell Therapies and Accelerating Clinical POC

CHAIR: Xiaokui Zhang, PhD, Aspen Neuroscience, United States


  • Adrienne Farid, PhD, Century Therapeutics, United States
  • Xiaokui Zhang, PhD, Aspen Neuroscience, United States
  • Shigeto Shimmura, MD, PhD, Fujita Health University; Japanese Society for Regenerative Medicine, Japan

Entering the MSC 2.0 Era: MSCs as Cellular Building Blocks for Next Generation Therapies

CHAIR: Jon Rowley, PhD, RoosterBio, United States


  • Gi-Hoon Nam, MD, PhD, SHIFTBIO Inc. & Korea University College of Medicine, Republic of Korea
  • Sarindr "Ik" Bhumiratana, PhD, EpiBone, United States
  • Remo Moomiaie-Qajar, MD, Cytonus Therapeutics, United States

Accelerating Your Product Timeline to Market by Keeping Up with Process Development Advancements

CHAIR: Lise Munsie, PhD, CCRM, Canada


  • Kimberly Schultz, MD, FDA, United States
  • Nooshafarin Sanaie, PhD, Poseida Therapeutics, Inc., United States
  • Janet Rothberg, PhD, CCRM, Canada

Overlooked and Underappreciated Non-MSC Exosomes

CHAIR: Sai Kiang Lim, PhD, Paracrine Therapeutics, Singapore


  • Yong Song Gho, PhD, Pohang University of Science and Technology, South Korea
  • Marca Wauben, PhD, Utrecht University, Netherlands
  • Naohiro Seo, PhD, The University of Tokyo, Japan

Purposeful Cellular and Microbiome Engineering—Not Just CAR-Ts

CHAIR: Sowmya Viswanathan, PhD, University Health Network, Canada


  • Carolina Tropini, PhD, PLEng, University of British Columbia, Canada
  • Megan Levings, PhD, University of British Columbia, Canada
  • Rita Barcia, PhD, Independent Expert, United States


Addresses topics arising in moving from Phase I of clinical trials through to marketing authorization, including results of promising Phase II/III clinical trials, discussions of regulatory requirements and barriers to approval, COGs, business models and operational structures to scale up, partnering and investment.


Witness the application of CRISPR-edited cells to patients, revolutionizing the very fabric of genetic medicine. Delve into the promising realm of in vivo applications, envisioning a future where gene editing occurs directly within the human body.

Explore the transformative potential of antisense technology in tackling ultra-rare genetic diseases, offering hope to individuals long overlooked by traditional medical approaches. Join us for an impactful journey into the exciting cell and gene therapy frontier where science fiction becomes medical reality.


Accelerated Approvals: The Viability of Surrogate Endpoints

CHAIR: Mo Heidaran, PhD, Cellx Inc., United States


  • Wilson Bryan, MD, Independent Regulatory Consultant, United States
  • Kemi Olugemo, MD, FAAN, Korro Bio, United States
  • David Lebwohl, MD, Intellia Therapeutics, Inc., United States

The Cutting-Edge of Stem Cell Genetic Innovation

CHAIR: Bruce Levine, PhD, University of Pennsylvania, United States


  • Alice Bertaina, MD, PhD, Stanford Medicine, United States
  • Susan Prockop, MD, Boston Children's Hospital, United States


  • Jaap Jan Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, United States

Unlocking the Value of Your Clinical Study

CHAIR: Sven Kili, MBChB, MRCS (Eng), CCRM, OmniaBio, United Kingdom


  • Patrick Rivers, MBA, Aquilo Capital Management, United States
  • Daniella Kranjac, ChEng, MBA, Avant Bio, United States
  • Sven Kili, MBChB, MRCS (Eng), CCRM, OmniaBio, United Kingdom

From Attackers to Allies: Engineering Cells to Quench the Autoimmune Inferno

CHAIR: Anthony Ting, PhD, Kiji Therapeutics, United States


  • Michael Aigner, PhD, University Hospital of Erlangen, Germany
  • Tracey Lodie, PhD, Quell Therapeutics, United States
  • Peter Maag, PhD, Kyverna Therapeutics, United States

Enabling Gene Editing Platforms for Novel In Vivo and Ex Vivo Therapeutics

CHAIR: Uma Lakshmipathy, PhD, Thermo Fisher, United States


  • Bruce Levine, PhD, University of Pennsylvania, United States
  • Fyodor Urnov, PhD, University of California, Berkeley, United States
  • Laura Sepp-Lorenzino, PhD, Intellia Therapeutics, United States


Addresses topics arising in bringing about the clinical adoption of market-authorized CGT products for patients globally, for example, discussions on pricing and reimbursement, business models, scaling up and scaling out, global launch strategies, and real-world evidence.


Building upon the experience of late-stage and commercial stakeholders, the session progresses operational excellence and broader patient access to CGTs by serving as a collaborative platform to build the roadmap for maturing our field.

As a community, we recognize the clinical and commercial milestones, and celebrate the transformational impact for patients, but we remain committed to addressing the challenges. This Plenary session will feature experiences and considerations towards operational execution, challenges and concerns about cell/gene/tissue-based therapies for society, and insights into these therapies as viable and sustainable models. Bring your thinking caps to learn, and your hard hats to get to work so that we can continue to pave the future of cell and gene therapies.


Industrializing Manufacturing & Distribution

CHAIR: Madhusudan V. Peshwa, PhD, Independent Expert, United States


  • Simon Gardiner, PhD, Kite Pharma, United States
  • Martin Westberg, MSc, Cytiva, Sweden


  • Nirupama Pike, MDS, PhD, Catalent Pharma Solutions, United States
  • Julie Allickson, PhD, Mayo Clinic, United States

Value and Reimbursement

CHAIR: Tania Bubela, BSc (Hons), PhD, JD, FCAHS, FRSC, Simon Fraser University, Canada


  • Doug Danison, MBA, Bayer, United States
  • Dean Regier, PhD, University of British Columbia & BC Cancer, Canada
  • Brad Groves, PhD, MAP Patient Access Limited, United Kingdom

Reimagining Patient Access

CHAIR: Mark Flower, BSc, Cryoport, United States


  • Peter Holman, ArsenalBio, United States
  • Antinea Chair, BSc, Cellares, United States
  • Julie Kanter, MD, University of Alabama at Birmingham, United States
  • Matthew L. Plaud, MSM, Cryoport, United States

Are In Vivo Cell Therapies the Future?

CHAIR: Madhusudan V. Peshwa, PhD, Independent Expert, United States


  • Michael Holmes, PhD, Tessera Therapeutics, United States
  • Christopher Wegener, MS, BME, Fresenius Kabi, United States


  • Dalip Sethi, PhD, MBA, Terumo BCT, United States
  • David Perritt, PhD, Lupagen, United States

Rare Diseases and Patient Access - The Mission and The Challenges

CHAIR: Susan B. Nichols, BSc, Propel Bio LLC, United States


  • Donald Kohn, MD, University of California, Los Angeles, United States
  • Susan B. Nichols, BSc, Propel Bio LLC, United States